MCAS Stratification: Not All Activation Patterns Are the Same
Mast Cell Activation Syndrome stratified into Pattern A/B/C/D phenotypes — diagnostic criteria, common misdiagnoses, and why treatment must differ by pattern.
The problem with "standard" MCAS treatment
Functional medicine approaches to MCAS typically follow this template: low-histamine diet, stabilizing supplements (quercetin, cromolyn, ketotifen), trigger avoidance. This works for some patients. For others it fails spectacularly.
Why? Because MCAS isn't one disease. It's a spectrum of mast cell dysfunction, and the mechanism differs by phenotype. Treating Pattern B (dysbiosis-driven) with a low-histamine diet alone is like treating dysbiosis with antihistamines — addressing the symptom, not the disease.
Pattern A: histamine-release dominant (30–40%)
Presentation: acute, rapid onset (minutes to under an hour); flushing, urticaria, pruritus; GI cramping and urgency; respiratory wheezing; identifiable consistent triggers (specific foods, stress, heat, cold); tryptase usually normal; histamine elevated during attacks; excellent response to antihistamines.
Mechanism: mast cells are hyper-excitable with a low degranulation threshold. Degranulation dominates over secretion; histamine is the primary mediator.
Treatment: H1 blocker (cetirizine, fexofenadine) plus H2 blocker (famotidine); strict low-histamine diet; cromolyn sodium dosed before triggers; epinephrine auto-injector for severe reactions; trigger avoidance. Prognosis is the best of the four phenotypes.
Pattern B: mediator secretion plus dysbiosis-linked (30–40%)
Presentation: subacute onset (hours to days); multisystem involvement simultaneously; chronic GI symptoms beyond acute attacks; brain fog, anxiety, mood instability ("mast cell brain"); flushing present but secondary; baseline tryptase elevated (1.5–5 ng/mL); concurrent SIBO or dysbiosis; elevated calprotectin; only partial response to antihistamines.
Mechanism: chronic mast cell activation driven by dysbiotic metabolites (H₂S, D-lactic acid, LPS). Secondary to colonocyte energy deficit and barrier breakdown. Treat the dysbiosis and mast cell activation often resolves.
Treatment: address dysbiosis first (antimicrobials, NAD+ restoration, butyrate support — see SIBO Protocol). Add stabilization second: H1/H2 blockers, cromolyn, quercetin, consider Low-Dose Naltrexone if inflammation persists.
Pattern C: tryptase-secretion dominant (15–25%)
Presentation: chronic, insidious symptoms — not classic acute histamine release; multisystem inflammation (joint pain, muscle aches, fatigue, malaise); baseline tryptase >3 ng/mL, sometimes >5–10; brain fog, cognitive dysfunction; low-histamine diet has minimal impact; poor response to antihistamines; may have elevated IgE or clonal markers.
Mechanism: persistent activation with continuous tryptase, heparin, and serine protease secretion. Tryptase activates PAR-2, driving systemic inflammation. Often associated with mastocytosis spectrum or clonal disease. Not driven by dysbiosis.
Treatment: tryptase-targeted stabilization — imatinib if KIT D816V confirmed, high-dose cromoglycate, or midostaurin for clonal disease. Anti-inflammatory support: curcumin, resveratrol, omega-3s, polyphenols. Often requires rheumatology or hematology involvement.
Pattern D: mixed / dysbiotic-driven MCAS (10–20%)
Presentation: symptoms fluctuate based on dysbiosis status — this is the defining feature. MCAS-like symptoms worsen when dysbiosis worsens. High calprotectin, elevated tryptase, dysbiotic bacterial profile. Frequently SIBO or H₂S overgrowth. Variable response to antihistamines. Dramatic improvement with dysbiosis treatment.
Mechanism: dysbiotic bacteria (especially H₂S-producers and gram-negatives) directly trigger mast cell degranulation. LPS translocation activates TLR4. H₂S activates PAR-2. The "MCAS" is secondary to dysbiosis and barrier breakdown — dysbiosis is the primary lesion.
Treatment: address dysbiosis first using the full Host Capacity protocol. Most patients respond dramatically — symptoms often resolve 70–80% when the dysbiotic ecosystem is restored. Mast cell stabilizers often become unnecessary.
Stratification table
| Feature | Pattern A | Pattern B | Pattern C | Pattern D |
|---|---|---|---|---|
| Tryptase baseline | Normal | 1.5–5 | >3, often >5 | Normal–mild |
| Calprotectin | Normal | Often high | Normal/low | High |
| Dysbiosis present | No | Often yes | No | Yes |
| Symptom onset | Minutes | Hours–days | Insidious | Fluctuates |
| Antihistamine response | Excellent | Partial | Poor | Variable |
| Dysbiosis Rx response | N/A | High | N/A | Dramatic |
Closing: the path forward
MCAS stratification allows targeted treatment instead of shotgun supplementation. Pattern A requires antihistamines and stabilizers. Patterns B and D require dysbiosis treatment, with mast cell stabilization secondary. Pattern C requires tryptase-targeted pharmaceuticals. If your MCAS isn't responding to standard approaches, a mechanistic re-read can identify which pattern you have — and which interventions will actually move the needle.
Frequently asked questions
Related reading
Map your case to mechanisms.
Seven brief questions. Get a preliminary mechanistic hypothesis and a 4-phase protocol framework, generated for your specific pattern.